November 29, 2022 – NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of nivolumab (Opdivo) plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.1